NVAX:NASDAQ
Novavax Inc
$9.42
arrow_upward
+1.29%(+0.12) 1D
$9.39
arrow_downward
-0.32% (-0.030)todayPre-market
Closed: Sep 11, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
$9.29
High
$9.86
Low
$9.23
Mkt. cap
1.55B
Avg. vol.
4.84M
Volume
17.42K
52-wk high
$11.97
52-wk low
$6.20
EPS
-$1.52
Beta
2.45
Shares outstanding
164.95M
No. of employees
749
Open
$9.29
High
$9.86
Low
$9.23
Mkt. cap
1.55B
Avg. vol.
4.84M
Volume
17.42K
52-wk high
$11.97
52-wk low
$6.20
EPS
-$1.52
Beta
2.45
Shares outstanding
164.95M
No. of employees
749
News stories
From web sources and news partners
Yahoo Finance
·
2 days ago
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitenovavax.com